![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CBX4 |
Gene summary for CBX4 |
![]() |
Gene information | Species | Human | Gene symbol | CBX4 | Gene ID | 8535 |
Gene name | chromobox 4 | |
Gene Alias | NBP16 | |
Cytomap | 17q25.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | A0A0S2Z5B2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8535 | CBX4 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.33e-06 | 1.51e-01 | 0.0155 |
8535 | CBX4 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.05e-02 | 1.49e-01 | -0.1954 |
8535 | CBX4 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.40e-02 | 1.04e-01 | -0.1464 |
8535 | CBX4 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.34e-03 | 1.97e-01 | -0.059 |
8535 | CBX4 | HTA11_866_3004761011 | Human | Colorectum | AD | 6.67e-08 | 1.92e-01 | 0.096 |
8535 | CBX4 | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.29e-09 | 2.25e-01 | 0.0674 |
8535 | CBX4 | HTA11_6818_2000001021 | Human | Colorectum | AD | 3.23e-07 | 2.64e-01 | 0.0588 |
8535 | CBX4 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.66e-23 | 5.09e-01 | 0.294 |
8535 | CBX4 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.06e-05 | 2.93e-01 | 0.281 |
8535 | CBX4 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 8.78e-46 | 9.23e-01 | 0.3859 |
8535 | CBX4 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.63e-09 | 4.94e-01 | 0.2585 |
8535 | CBX4 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 9.85e-29 | 6.08e-01 | 0.3005 |
8535 | CBX4 | LZE4T | Human | Esophagus | ESCC | 6.97e-06 | 2.90e-04 | 0.0811 |
8535 | CBX4 | LZE7T | Human | Esophagus | ESCC | 3.20e-02 | 2.10e-01 | 0.0667 |
8535 | CBX4 | LZE8T | Human | Esophagus | ESCC | 3.05e-05 | 7.01e-02 | 0.067 |
8535 | CBX4 | LZE20T | Human | Esophagus | ESCC | 2.30e-02 | 4.50e-02 | 0.0662 |
8535 | CBX4 | LZE22D1 | Human | Esophagus | HGIN | 1.78e-02 | 2.14e-02 | 0.0595 |
8535 | CBX4 | LZE22T | Human | Esophagus | ESCC | 4.96e-03 | 8.10e-02 | 0.068 |
8535 | CBX4 | LZE24T | Human | Esophagus | ESCC | 3.63e-13 | 5.18e-01 | 0.0596 |
8535 | CBX4 | P1T-E | Human | Esophagus | ESCC | 4.51e-04 | 4.29e-01 | 0.0875 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001820531 | Oral cavity | NEOLP | peptidyl-lysine modification | 64/2005 | 376/18723 | 1.21e-04 | 1.43e-03 | 64 |
GO:001692521 | Oral cavity | NEOLP | protein sumoylation | 12/2005 | 53/18723 | 9.03e-03 | 4.31e-02 | 12 |
GO:00182055 | Prostate | BPH | peptidyl-lysine modification | 96/3107 | 376/18723 | 5.70e-06 | 8.39e-05 | 96 |
GO:00063259 | Prostate | BPH | chromatin organization | 101/3107 | 409/18723 | 1.52e-05 | 1.94e-04 | 101 |
GO:00169252 | Prostate | BPH | protein sumoylation | 18/3107 | 53/18723 | 1.56e-03 | 9.16e-03 | 18 |
GO:001820512 | Prostate | Tumor | peptidyl-lysine modification | 99/3246 | 376/18723 | 6.77e-06 | 1.02e-04 | 99 |
GO:000632514 | Prostate | Tumor | chromatin organization | 104/3246 | 409/18723 | 2.02e-05 | 2.62e-04 | 104 |
GO:00169251 | Prostate | Tumor | protein sumoylation | 18/3246 | 53/18723 | 2.59e-03 | 1.43e-02 | 18 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CBX4 | SNV | Missense_Mutation | c.952N>C | p.Glu318Gln | p.E318Q | O00257 | protein_coding | tolerated(0.07) | possibly_damaging(0.749) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CBX4 | SNV | Missense_Mutation | c.530N>G | p.His177Arg | p.H177R | O00257 | protein_coding | tolerated(0.23) | benign(0.079) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
CBX4 | SNV | Missense_Mutation | rs760922762 | c.1000N>A | p.Gly334Arg | p.G334R | O00257 | protein_coding | tolerated(0.24) | benign(0) | TCGA-C5-A1ME-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CBX4 | SNV | Missense_Mutation | c.1456G>A | p.Glu486Lys | p.E486K | O00257 | protein_coding | tolerated(0.12) | benign(0.068) | TCGA-DS-A0VN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
CBX4 | SNV | Missense_Mutation | c.127N>A | p.Glu43Lys | p.E43K | O00257 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-SS-A7HO-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | oxaliplatin | PD | |
CBX4 | deletion | Frame_Shift_Del | novel | c.862delN | p.Glu288ArgfsTer117 | p.E288Rfs*117 | O00257 | protein_coding | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
CBX4 | insertion | Frame_Shift_Ins | rs772839792 | c.690dupC | p.Asn231GlnfsTer81 | p.N231Qfs*81 | O00257 | protein_coding | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
CBX4 | SNV | Missense_Mutation | novel | c.420G>T | p.Lys140Asn | p.K140N | O00257 | protein_coding | deleterious(0.01) | possibly_damaging(0.535) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CBX4 | SNV | Missense_Mutation | c.733N>A | p.Gly245Arg | p.G245R | O00257 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CBX4 | SNV | Missense_Mutation | c.890G>A | p.Arg297Gln | p.R297Q | O00257 | protein_coding | deleterious(0.02) | benign(0.01) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |